DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Corona Remedies Limited (CORONA) share price today?

Corona Remedies Limited (CORONA) is trading at ₹2,037.5 on the NSE, down 0.36% on the day. Source: DocStoX.

What is the PE ratio of Corona Remedies Limited?

Corona Remedies Limited has a price-to-earnings (PE) ratio of 67.3 in the Healthcare sector.

What is the market capitalisation of Corona Remedies Limited?

Corona Remedies Limited has a market capitalisation of approximately ₹12,256 crore.

Is Corona Remedies Limited a profitable company?

Corona Remedies Limited generates a return on equity of 24.8% with a net profit margin of 13.2%. That is a strong return on shareholder capital.

What is the 52-week high and low of CORONA?

Corona Remedies Limited (CORONA) has traded between ₹1,329.32 and ₹2,292.4 over the past 52 weeks, against a current price of ₹2,037.5.

Does Corona Remedies Limited pay a dividend?

Yes. Corona Remedies Limited currently offers a dividend yield of 0.49%. Dividend payments depend on the board's declaration each year.

Corona Remedies Limited

₹2,037.50▼ -7.30 (-0.36%)

CORONA·NSE·Healthcare

Market Cap

12255.87 Cr

PE Ratio

67.31

Volume

93,648

Day High - Low

2065.40 - 1995.00

52W High-Low

2292.40 - 1329.32

₹2,037.50▼ -7.30 (-0.36%)

Market Cap12255.87 Cr

PE Ratio67.31

Volume93,648

Day High - Low2065.40 - 1995.00

52W High-Low2292.40 - 1329.32

Corona Remedies Limited (CORONA): company summary

The company's business is improving, with annual revenue rising 17.3% and annual net profit rising 24.2%.

Corona Remedies Limited (CORONA) is a small-cap Healthcare company valued at ₹12,256 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Corona Remedies Limited last traded at ₹2,037.5, modestly down 0.36% on the day.
Recent developments: On 2026-06-19, the company announced a dividend of ₹10.00 per share, with the ex-date set for that day. Promoter holding remained at 69.00% as of 2026-06-30. Foreign institutional holding increased by 1.38 percentage points, and domestic institutional holding increased by 5.88 percentage points in the quarter.
Financial performance: The company's business is improving, with annual revenue rising 17.3% and annual net profit rising 24.2%. The latest quarter saw revenue rise 21.7% and net profit rise 30.7% compared to the same quarter a year earlier. The net profit margin increased by 0.7 percentage points to 13.2%, while return on equity remained at 24.8%.
Valuation multiples: The stock trades at 67.3 times earnings, a premium to the Healthcare median of 32.0, 16.49 times book value. It yields 0.5%.
Things to watch: The stock is 11.5% below its 52-week high. Promoter holding is 69.00%, and foreign institutional holding is 3.63%. Domestic institutional holding is 12.90%. The company's last price is ₹2,029.40, down 3.06% for the day.
Where it stands: The company's latest quarter revenue and net profit both rose compared to the same quarter a year earlier. The stock is 11.5% below its 52-week high. The company's last price is ₹2,029.40.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.3/10

Fair

Fair Value

ROE

24.79%

Strong

P/E

67.31x

Expensive

Debt / Equity

0.19

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹1995

₹2065

52W₹1329

₹2292

DocStoX take

Supported by risk (8.7) and growth (7.8), but held back by valuation (0.0). Risk looks strong at 8.7, but that is offset by valuation at 0.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.3

/10

Fair

Quality

Excellent

ROE 24.8%

Valuation

Expensive

P/E 67.3×

Growth

Strong

Revenue +19.5% 5Y CAGR

Risk

Low risk

D/E 0.19

Momentum

Strong

74% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹2,038

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹12,256 Cr

52W High / Low

₹2292 / ₹1329

Dividend Yield

0.49%

Promoter Holding

69.00%

EPS (TTM)

₹30.27

Book Value

₹122.12

Key highlights

Low leverage — D/E 0.19
Capital works hard — ROCE 28%
Strong returns on equity (25%)
Valuation is weak (0.0/10)
Expensive at 67× earnings

4 Positives2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore CORONA REMEDIES LIMITED’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

CORONA REMEDIES LIMITED peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD LAURUS LABS LIMITED CIPLA LTD DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD MANKIND PHARMA LIMITED LUPIN LIMITED MANIPAL HEALTH ENTERPRI L

Compare CORONA REMEDIES LIMITED with peers

CORONA REMEDIES LIMITED vs SUN PHARMACEUTICAL IND L CORONA REMEDIES LIMITED vs DIVI S LABORATORIES LTD CORONA REMEDIES LIMITED vs TORRENT PHARMACEUTICALS L CORONA REMEDIES LIMITED vs APOLLO HOSPITALS ENTER. L CORONA REMEDIES LIMITED vs ZYDUS LIFESCIENCES LTD CORONA REMEDIES LIMITED vs LAURUS LABS LIMITED

Related tools & concepts

Value CORONA REMEDIES LIMITED with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

CORONA newsLatest coverage & filings Open screenerFilter the whole market